<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810768</url>
  </required_header>
  <id_info>
    <org_study_id>MIRACLE I</org_study_id>
    <nct_id>NCT03810768</nct_id>
  </id_info>
  <brief_title>Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness</brief_title>
  <acronym>MIRACLE I</acronym>
  <official_title>Metabolomics Pilot Study on Postoperative Intensive Care Acquired Muscle Weakness (MIRACLE-I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this mono-center pilot trial, surgical patients who are at high risk to be admitted to
      intensive care will be screened and asked for participation. We are going to take blood and
      muscle samples at respecified time points to do metabolic, histological and molecular
      testing.

      Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW
      (intensive care unit acquired weakness) and (2) identify metabolic components who are
      responsible for ICUAW or can be used as marker for ICUAW.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Blood Metabolome will be isolated from blood samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) using mass spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle histology</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Immunohistochemistry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphoproteomics</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify possible predictors of muscle wasting in the blood metabolome preoperatively</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) preoperatively associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Identify possible predictors of muscle wasting in the blood metabolome at ICU admission</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metabolomics</condition>
  <condition>Critical Care</condition>
  <condition>Critical Illness</condition>
  <condition>Critical Illness Myopathy</condition>
  <condition>Critical Illness Polyneuropathy</condition>
  <condition>Intensive Care (ICU) Myopathy</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Intensive Care Patients</arm_group_label>
    <description>Postoperative high-risk patients who have been admitted to intensive care after surgery</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood

        -  Skeletal muscle biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        postoperative high-risk patients who are admitted to intensive care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  surgical patients with a high risk being admitted to intensive care since they will
             undergo a high risk surgery and have severe comorbidities (ASA III or IV)

          -  signed informed consent

          -  intensive care stay &gt; 3d

        Exclusion Criteria:

          -  emergency surgery

          -  intensive care admission primarily due to neurological reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stefan J Schaller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hennig Wackerhage, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan J Schaller, MD</last_name>
    <phone>+49-89-4140-9635</phone>
    <email>s.schaller@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manfred Blobner, MD</last_name>
    <phone>+49-89-4140-7206</phone>
    <email>m.blobner@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, School of Medicine, Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan J Schaller, MD</last_name>
      <phone>+49-89-4140-9635</phone>
      <email>s.schaller@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Manfred Blobner, MD</last_name>
      <phone>+49-89-4140-7206</phone>
      <email>m.blobner@tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan J Schaller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henning Wackerhage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manfred Blobner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Schlegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Stefan Schaller</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pilot trial</keyword>
  <keyword>muscle biopsy</keyword>
  <keyword>blood metabolome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

